A diagnosis of Group A Streptococcus (GAS), most commonly known for causing strep throat or scarlet fever, can bring intense discomfort, including a sudden onset of fever and severe sore throat. While these common infections are usually disruptive but not life-threatening, it is crucial to recognize that this bacteria can also cause more serious skin infections or, rarely, invasive diseases. Beyond the immediate relief of fever and pain, treatment for Group A Streptococcal Infection is essential to prevent severe, non-suppurative complications, most notably acute rheumatic fever and post-streptococcal glomerulonephritis (kidney inflammation).

Treatment focuses on eliminating the bacteria completely to prevent the immune system from mistakenly attacking the body’s own tissues (a process known as post-infectious complication). Treatment needs depend on the severity; while typical strep throat is an acute case, more severe invasive infections require immediate hospital care. Medication is the absolute core of treating GAS infections, as the body requires assistance to clear the bacteria before complications can arise (Centers for Disease Control and Prevention, 2023).

Overview of treatment options for Streptococcal Group A Infection

The main goal of treatment for GAS infection is bacterial eradication. Complete elimination of the bacteria is necessary not just to relieve symptoms, but to eliminate the risk of late-onset immune-mediated complications like rheumatic fever. Because the infection is caused by bacteria, treatment relies almost exclusively on antibiotics.

For common infections like strep throat, an oral antibiotic course is highly effective. In rare, severe cases, such as necrotizing fasciitis or Streptococcal Toxic Shock Syndrome, treatment involves immediate, aggressive therapy that includes high-dose intravenous antibiotics and often supportive procedures, such as surgical removal of infected tissue. Unlike viral illnesses, lifestyle measures alone cannot cure a GAS infection, making prompt medication use mandatory.

Medications used for Streptococcal Group A Infection

Antibiotics are the primary drug class used to treat GAS infections. Treatment protocols are standardized and highly successful because Group A Streptococcus has generally remained sensitive to certain historical antibiotics.

1. Penicillin Class (First-Line): The preferred and most common treatment is a penicillin-based antibiotic, such as Penicillin V or Amoxicillin. These drugs are effective, inexpensive, and generally well-tolerated. Penicillin is the agent of choice because studies show it is almost universally effective against GAS and has the longest track record of preventing rheumatic fever. Symptoms like fever and sore throat usually begin to improve within 24 to 48 hours after starting the medication.

2. Second-Line and Allergy Alternatives: For patients who have a known penicillin allergy, macrolide antibiotics are often prescribed. Examples include azithromycin and clarithromycin. In cases where there is concern about antibiotic resistance or for more serious skin infections, clindamycin may be used. Clindamycin has the added benefit of suppressing the production of toxins released by the bacteria, making it a critical drug for severe, invasive infections.

3. Supportive Care: While not an antibiotic, supportive care is crucial. Over-the-counter pain relievers and fever reducers, such as ibuprofen or acetaminophen, are essential for managing symptoms while the antibiotic begins to work.

How these medications work

Antibiotics for Group A Strep (GAS) target bacterial structures absent in human cells. Penicillin-class antibiotics are cell wall inhibitors; they prevent the bacteria from building and repairing its cell wall, causing the cell to burst and die, thus rapidly clearing the infection.

Macrolides and clindamycin inhibit protein synthesis by blocking the bacteria’s ribosomes. This stops protein production, preventing bacterial survival and multiplication. Eliminating the bacteria is crucial to halt the immune stimulation that leads to post-infectious complications.

Side effects and safety considerations

Antibiotics are generally safe, but side effects, mainly gastrointestinal (nausea, vomiting, cramps, diarrhea), are common. Diarrhea can stem from disrupting healthy gut bacteria, rarely leading to C. difficile overgrowth.

The most serious risk is an allergic reaction, especially to penicillin, ranging from a mild rash to life-threatening anaphylaxis. Seek immediate care for hives, facial swelling, or breathing difficulty. It is vital to complete the full prescribed course; stopping early risks relapse and complications like rheumatic fever.

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Centers for Disease Control and Prevention. https://www.cdc.gov
  2. Mayo Clinic. https://www.mayoclinic.org
  3. National Institutes of Health. https://www.nih.gov
  4. MedlinePlus. https://medlineplus.gov

Medications for Streptococcal Group A Infection

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Streptococcal Group A Infection.

Found 14 Approved Drugs for Streptococcal Group A Infection

Azithromycin

Brand Names
Azasite, Zithromax

Azithromycin

Brand Names
Azasite, Zithromax
Azithromycin for oral suspension USP is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

Clindamycin

Brand Names
ClindaCare, Cleocin, Xaciato, Neuac, Clindacin ETZ, Clindesse, Clindacin, Tretinoin, Clindamycin Phoaphate, Atralin, Twyneo, Altreno, ZIANA, Tri-Luma, Retin-A, Clindagel, Acanya, Renova, Onexton

Clindamycin

Brand Names
ClindaCare, Cleocin, Xaciato, Neuac, Clindacin ETZ, Clindesse, Clindacin, Tretinoin, Clindamycin Phoaphate, Atralin, Twyneo, Altreno, ZIANA, Tri-Luma, Retin-A, Clindagel, Acanya, Renova, Onexton
TWYNEO is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. TWYNEO is a combination tretinoin, a retinoid, and benzoyl peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. ( 1 )

CefTRIAXone

Generic Name
CefTRIAXone

CefTRIAXone

Generic Name
CefTRIAXone
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections Caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media Caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy. Skin and Skin Structure Infections Caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis * or Peptostreptococcus species. Urinary Tract Infections (complicated and uncomplicated) Caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea (cervical/urethral and rectal) Caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. Pelvic Inflammatory Disease Caused by Neisseria gonorrhoeae. Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone and Joint Infections Caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-abdominal Infections Caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis Caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis * and Escherichia coli*. * Efficacy for this organism in this organ system was studied in fewer than ten infections. Surgical Prophylaxis The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure.

Clarithromycin

Generic Name
Clarithromycin

Clarithromycin

Generic Name
Clarithromycin
Clarithromycin is a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: Acute Bacterial Exacerbation of Chronic Bronchitis in Adults.

Ofloxacin

Brand Names
Ocuflox, Ofloxacin Ophth, Olfoxacin

Ofloxacin

Brand Names
Ocuflox, Ofloxacin Ophth, Olfoxacin
Ofloxacin Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections.
Showing 1-5 of 14
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances